Among patients with refractory large B cell lymphoma (LBCL), chimeric antigen receptor (CAR)-T cell therapy appears to yield superior long-term clinical outcomes to those seen with standard salvage therapy regimens, according to an analysis published in Blood Advances. Treatments for LBCL, the most common non-Hodgkin lymphoma subtype, have improved over the...
research News
Chimeric antigen receptor T-cell (CAR-T) therapy has demonstrated effectiveness and safety in relapsed/refractory multiple myeloma (RRMM), according to a meta-analysis published in the International Journal of Medical Sciences. RRMM treatments have come a long way and have drastically improved overall survival, but the disease remains incurable. CAR-T therapy has led to...
STAMFORD, Conn. — Cara Therapeutics, Inc. today announced it will focus its resources on the oral difelikefalin Phase 2/3 clinical program in notalgia paresthetica (NP) and significantly reduce its operating expenses. These measures will extend the Company’s cash runway into 2026, enabling the expected completion of the NP clinical program....
MADISON — A fundamental question about how sugar units are strung together into long carbohydrate chains has also pinpointed a promising way to target new medicines against tuberculosis. Working with components of the tuberculosis bacterium, researchers from the University of Wisconsin-Madison identified an unusual process by which the pathogen builds...
DURHAM, N.C. — Restricting carbohydrates, regardless of weight loss, appears to slow the growth of prostate tumors, according to an animal study being published this week by researchers in the Duke Prostate Center. “Previous work here and elsewhere has shown that a diet light in carbohydrates could slow tumor growth,...
SAN DIEGO, Calif. — Cardiff Oncology, Inc., a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that the findings of the Phase 1b portion of the Phase 1b/2 study for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC)...
SAN DIEGO, Calif. — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that the first patient was dosed in its randomized first-line Phase 2 trial, CRDF-004, for patients with RAS-mutated metastatic colorectal cancer (mCRC). The...
SHANGHAI, China — CARsgen Therapeutics Holdings Ltd, a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that CT011, an autologous CAR T-cell product candidate against Glypican-3 (GPC3), has achieved Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA)...
Shijiazhuang, China – A teenage girl was diagnosed with concomitant Wilson disease (WD) and systemic lupus erythematosus (SLE), according to a case report published in Frontiers in Pediatrics. The 17-year-old patient was initially diagnosed with SLE following positive tests for lupus anticoagulant and antinuclear antibodies, along with pleural effusion, hypocomplementemia,...
The use of tyrosine kinase inhibitor (TKI) therapy may provide a degree of protection against COVID-19 in patients with chronic myeloid leukemia (CML). These findings are suggested by in a case report and literature review published in the European Journal of Case Reports in Internal Medicine. The case report involved a...